Desirudin — Dose Evidence | Peptides Community

Reference only — not a dosing recommendation.

Approved regimen

Approved labeled regimen

Product-, indication-, and jurisdiction-specific — see the monograph

Elective hip replacement: 15 mg SC every 12 h. First dose given 5-15 min prior to surgery (but after induction of regional block anesthesia). Continue for 9-12 days. In moderate renal impairment (CrCl 31–60 mL/min): reduce dose by factor of 3 (5 mg SC q12h). In severe renal impairment (CrCl <31 mL/min): reduce dose by factor of 9 (1.7 mg SC q12h). Monitor aPTT and serum creatinine daily in patients with renal impairment.

Studied in trials

Studied regimens (not recommendations)

Studied in trials — not a recommended dose

Various dose-ranging studies used 10-20 mg SC BID; the 15 mg BID dose was selected as the optimal balance of efficacy and safety.

Not established

What is not established

DVT prophylaxis for knee replacement (not established; phase 3 data limited to hip replacement).
Treatment of established VTE (not labeled).
Use in ACS or PCI (not labeled; bivalirudin used instead for these indications).
Pediatric use.

Desirudin — monograph dose and administration evidence